Pfizer's Wyeth bid suffers influential ratings hit
This article was originally published in Scrip
Executive Summary
Pfizer's buyout of Wyethmay falter if credit rating agencies decide to lower their ratings for Pfizer. It has emerged that a syndicate funding one third of the deal can withdraw its financing commitments should Pfizer's credit rating drop below a certain threshold.